Navigation Links
Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual,Meeting of the American Association of Cancer Research (AACR)

NEW HAVEN, Conn., April 13, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced today that data on its lead anticancer agent Cloretazine(R) (VNP40101M) will be presented in posters at the 100th Annual Meeting of the American Association of Cancer Research in Los Angeles, California. All three posters will be available on Vion's website, www.vionpharm.com on the day of presentation.

All posters will be presented in the Los Angeles Convention Center Exhibit Hall at the times and locations listed below:

Poster #16 (section 31), entitled "Effects of Cloretazine(R) on multidrug resistant cell lines" will be presented on Sunday, April 15 from 1 to 5 p.m. These studies were designed to determine whether Cloretazine(R) has the potential to circumvent one of the most common mechanisms of resistance to cancer chemotherapy agents.

Poster # 5 (section 5) entitled "Low levels of pre-treatment O6 - alkylguanine transferase (AGT) in patients with AML correlate with response to Cloretazine(R) (VNP40101M) induction therapy" will be presented on Monday, April 16 from 1 to 5 p.m. Since overexpression of AGT has been associated with drug resistance preclinically, these data were collected as part of a Phase II clinical trial of Cloretazine(R) to assess whether pretreatment AGT levels could be correlated with response.

Poster #14 (section 27) entitled "Sequence dependent cytotoxocity of Cloretazine(R) in combination with anthracyclines" will be presented on Tuesday, April 17 from 1 to 5 p.m. These preliminary in vitro studies were designed to assess the effects of various sequences of administration of Cloretazine(R) and anthracyclines on cell survival and provide direction as to which combinations to further evaluate in preclinical models.

In addition to Vion's Cloretazine(R) (VNP40101M) posters, two posters will be presente d on Vion's second anticancer product, Triapine(R) at the meeting. Triapine(R) is in clinical trials sponsored by the National Cancer Institute.

Poster #7 (section 6) entitled "Pharmacokinetic and pharmacogenetic evaluation of Triapine(R)" will be presented on Sunday, April 15 from 1 to 5 p.m.

Poster #26 (section 7) entitled "Triapine(R) binds with iron and causes S- phase arrest and activation of the apoptotic pathway in advanced cancer patients" will be presented on Monday, April 16 from 8 a.m. to 12 p.m.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's p otential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    COMPANY CONTACT:  Vion Pharmaceuticals, Inc.

                      Alan Kessman, Chief Executive Officer

                      Howard B. Johnson, President & CFO

                      (203) 498-4210 phone

CONTACT: Alan Kessman, Chief Executive Officer, or Howard B. Johnson,President & CFO, +1-203-498-4210, both of Vion Pharmaceuticals, Inc.

Web site: http://www.vionpharm.com/

Ticker Symbol: (NASDAQ-NMS:VION)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):